AKTS — Aktis Oncology, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2035832 ·
Last close
$16.40
Market Cap
$884.37M
52W High
$34.19
52W Low
$13.96
ADV30
377,889
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 3,905,000 | — | -34,747,000 | -29,939,000 | 532,484,000 | 68,323,000 | 73,612,000 |
| Jun 2026 | 3,384,000 | — | -28,899,000 | -24,144,000 | 557,596,000 | 82,491,000 | 72,758,000 |
| Mar 2026 | 3,227,000 | — | -22,706,000 | -18,325,000 | 576,801,000 | 371,630,000 | 70,693,000 |
| Dec 2025 | 1,870,000 | — | -17,375,000 | -15,138,000 | 264,885,000 | 37,784,000 | 411,034,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-75,294,000
Investing CF
$-289,389,000
Financing CF
$336,959,000
CapEx
$-9,272,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.59
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-199,033,000
Inventory
—
Receivables
—
ST Investments
$434,829,000
EBIT TTM
$-87,183,000
Pretax Income TTM
$-73,140,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$12,386,000
EBITDA
$-100,559,000
Free Cash Flow
$-54,510,376
Enterprise Value
$445,266,176
Total Cash
$492,928,992
Total Debt
$10,835,000
Shares Out
53,925,016
Trailing EPS
$-1.70
Book Value
$8.23
ROE
-26.5%
ROA
-16.0%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,497,000 | -74,684,000 | -63,731,000 | 264,885,000 | 411,034,000 | -146,149,000 | -64,127,000 |
| Dec 2024 | 1,487,000 | -52,050,000 | -43,980,000 | 326,181,000 | 413,984,000 | -87,803,000 | 14,762,000 |
| Dec 2023 | 0 | -34,794,000 | -28,641,000 | 122,355,000 | 168,661,000 | -46,306,000 | -30,004,000 |
| Dec 2022 | 0 | -19,764,000 | -17,929,000 | 138,322,000 | 157,552,000 | -19,230,000 | -18,125,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$557,596,000
Forward EPS
$-2.21
Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $15.00 · spot: $16.40 · call volume: 35 · put volume: 11Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CTY | CITY THERAPEUTICS, INC. | $887.55M | $18.35 | — |
| MTRI | InMed Pharmaceuticals Inc. | $888.78M | $15.24 | — |
| LTGO | Latigo Biotherapeutics, Inc. | $877.80M | $13.24 | — |
| VSTM | Verastem, Inc. | $864.46M | $6.86 | — |
| PHAR | Pharming Group N.V. | $861.37M | $12.17 | — |
News headlines (Yahoo Finance, 1h cache)
Aktis: Q3 Earnings Snapshot
2026-11-12 13:23 · Yahoo
Aktis Oncology Reports Third-Quarter Financial Results and Highlights Clinical Trial Progress
2026-11-12 13:00 · Yahoo
Does Aktis (AKTS) Have the Potential to Rally 105.62% as Wall Street Analysts Expect?
2026-11-11 20:19 · Yahoo
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
2026-10-01 12:00 · Yahoo
Aktis Oncology to Present at Upcoming September Investor Conferences
2026-09-09 12:00 · Yahoo
Aktis Oncology Seen Advancing Targeted Radiation-Based Cancer Drugs, Wedbush Says
2026-08-19 15:42 · Yahoo
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
2026-08-13 20:01 · Yahoo
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2026-05-04 20:05 · Yahoo
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company
2026-05-13 20:30 · Yahoo
Aktis Oncology Details Two-Phase 1b Plan for AKY-2519 in Prostate Cancer and Solid Tumors
2026-05-05 14:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.